Meghan Lyman

Meghan Lyman

Auto-generated profile, based on publicly available information

Meghan Lyman

Mycotic Diseases Branch, Centers for Disease Control and Prevention , Atlanta, Georgia

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2023 in Annals of Internal Medicine
Verified
Journal Article
Closed access
MLMeghan Lyman
Meghan Lyman
KFKaitlin Forsberg
Kaitlin Forsberg
DSD. Joseph Sexton
D. Joseph Sexton
NCNancy A. Chow
Nancy A. Chow
Shawn R LockhartShawn R Lockhart
Shawn R Lockhart
TCTom M. Chiller
Tom M. Chiller
Candida auris is an emerging fungal threat that has been spreading in the United States since it was first reported in 2016. To describe recent changes in the U.S. epidemiology of C auris occurring from 2019 to 2021. Description of national surveillance data. United States. Persons with any specimen that was positive for C auris. Case counts reported to the Centers for Disease Control and Prevention by health departments, volume of colonization screening, and antifungal susceptibility results were aggregated and compared over time and by geographic region. A total of 3270 clinical cases and 7413 screening cases of C auris were reported in the United States through 31 December 2021. The percentage increase in clinical cases grew each year, from a 44% increase in 2019 to a 95% increase in 2021. Colonization screening volume and screening cases increased in 2021 by more than 80% and more than 200%, respectively. From 2019 to 2021, 17 states identified their first C auris case. The number of C auris cases that were resistant to echinocandins in 2021 was about 3 times that in each of the previous 2 years. Identification of screening cases depends on screening that is done on the basis of need and available resources. Screening is not conducted uniformly across the United States, so the true burden of C auris cases may be underestimated. C auris cases and transmission have risen in recent years, with a dramatic increase in 2021. The rise in echinocandin-resistant cases and evidence of transmission is particularly concerning because echinocandins are first-line therapy for invasive Candida infections, including C auris. These findings highlight the need for improved detection and infection control practices to prevent spread of C auris. None.

23 July 2021 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Open access
MLMeghan Lyman
Meghan Lyman
KFKaitlin Forsberg
Kaitlin Forsberg
JRJacqueline Reuben
Jacqueline Reuben
TDThi Dang
Thi Dang
RFRebecca Free
Rebecca Free
TCTom Chiller
Tom Chiller

1 May 2017 in Emerging Infectious Diseases
Verified
Journal Article
Open access
MLMeghan M. Lyman
Meghan M. Lyman
CGCheri Grigg
Cheri Grigg
CKCara Bicking Kinsey
Cara Bicking Kinsey
MKM. Shannon Keckler
M. Shannon Keckler
HMHeather Moulton-Meissner
Heather Moulton-Meissner
KPKiran M. Perkins
Kiran M. Perkins
Invasive nontuberculous mycobacteria (NTM) infections may result from a previously unrecognized source of transmission, heater–cooler devices (HCDs) used during cardiac surgery. In July 2015, the Pennsylvania Department of Health notified the Centers for Disease Control and Prevention (CDC) about a cluster of NTM infections among cardiothoracic surgical patients at 1 hospital. We conducted a case–control study to identify exposures causing infection, examining 11 case-patients and 48 control-patients. Eight (73%) case-patients had a clinical specimen identified as Mycobacterium avium complex (MAC). HCD exposure was associated with increased odds of invasive NTM infection; laboratory testing identified patient isolates and HCD samples as closely related strains of M. chimaera, a MAC species. This investigation confirmed a large US outbreak of invasive MAC infections in a previously unaffected patient population and suggested transmission occurred by aerosolization from HCDs. Recommendations have been issued for enhanced surveillance to identify potential infections associated with HCDs and mitigate transmission risk.

5 June 2021 in Antimicrobial Resistance & Infection Control
Verified
Journal Article
Open access
PDF file
WPWantana Paveenkittiporn
Wantana Paveenkittiporn
MLMeghan Lyman
Meghan Lyman
CBCaitlin Biedron
Caitlin Biedron
NCNora Chea
Nora Chea
CBCharatdao Bunthi
Charatdao Bunthi
NJNoppavan Janejai
Noppavan Janejai
Background: Carbapenem-resistant Enterobacterales (CRE) is a global threat. Enterobacterales develops carbapenem resistance through several mechanisms, including the production of carbapenemases. We aim to describe the prevalence of Carbapenem-resistant Enterobacterales (CRE) with and without carbapenemase production and distribution of carbapenemase-producing (CP) genes in Thailand using 2016–2018 data from a national antimicrobial resistance surveillance system developed by the Thailand National Institute of Health (NIH). Methods: CRE was defined as any Enterobacterales resistant to ertapenem, imipenem, or meropenem. Starting in 2016, 25 tertiary care hospitals from the five regions of Thailand submitted the first CRE isolate from each specimen type and patient admission to Thailand NIH, accompanied by a case report form with patient information. NIH performed confirmatory identification and antimicrobial susceptibility testing and performed multiplex polymerase chain reaction testing to detect CP-genes. Using 2016–2018 data, we calculated proportions of CP-CRE, stratified by specimen type, organism, and CP-gene using SAS 9.4. Results: Overall, 4,296 presumed CRE isolates were submitted to Thailand NIH; 3,946 (93%) were confirmed CRE. Urine (n = 1622, 41%) and sputum (n = 1380, 35%) were the most common specimen types, while blood only accounted for 323 (8%) CRE isolates. The most common organism was Klebsiella pneumoniae (n = 2660, 72%), followed by Escherichia coli (n = 799, 22%). The proportion of CP-CRE was high for all organism types (range: 85–98%). Of all CRE isolates, 2909 (80%) had one CP-gene and 629 (17%) had > 1 CP-gene. New Delhi metallo-beta-lactamase (NDM) was the most common CP-gene, present in 2392 (65%) CRE isolates. K. pneumoniae carbapenemase (KPC) and Verona integron-encoded metallo-β-lactamase (VIM) genes were not detected among any isolates. Conclusion: CP genes were found in a high proportion (97%) of CRE isolates from hospitals across Thailand. The prevalence of NDM and OXA-48-like genes in Thailand is consistent with pattern seen in Southeast Asia, but different from that in the United States and other regions. As carbapenemase testing is not routinely performed in Thailand, hospital staff should consider treating all patients with CRE with enhanced infection control measures; in line with CDC recommendation for enhanced infection control measures for CP-CRE because of their high propensity to spread.

3 August 2023 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
DSDallas James Smith
Dallas James Smith
JGJeremy A.W. Gold
Jeremy A.W. Gold
KBKaitlin Benedict
Kaitlin Benedict
KWKaren Wu
Karen Wu
MLMeghan Lyman
Meghan Lyman
TCTom M. Chiller
Tom M. Chiller
Fungal infections can cause severe disease and death and impose a substantial economic burden on healthcare systems. Public health research requires a multidisciplinary approach and is essential to help save lives and prevent disability from fungal diseases. In this manuscript, we outline the main public health research priorities for fungal diseases, including the measurement of the fungal disease burden and distribution and the need for improved diagnostics, therapeutics, and vaccines. Characterizing the public health, economic, health system, and individual burden caused by fungal diseases can provide critical insights to promote better prevention and treatment. The development and validation of fungal diagnostic tests that are rapid, accurate, and cost-effective can improve testing practices. Understanding best practices for antifungal prophylaxis can optimize prevention in at-risk populations, while research on antifungal resistance can improve patient outcomes. Investment in vaccines may eliminate certain fungal diseases or lower incidence and mortality. Public health research priorities and approaches may vary by fungal pathogen.

6 March 2020 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
MLMeghan Lyman
Meghan Lyman
DNDuc B. Nguyen
Duc B. Nguyen
ASAlicia Shugart
Alicia Shugart
HGHeidi Gruhler
Heidi Gruhler
CLChristi Lines
Christi Lines
PPPriti R. Patel
Priti R. Patel